Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Niagen Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.398 Ladies and gentlemen, thank you for standing by, and welcome to the NIGEN Biosciences, 00:00:04.398 -- 00:00:08.505 Inc., third quarter of 2025 earnings conference call. 00:00:08.505 -- 00:00:11.229 My name is Tamika, and I will be your conference operator today. 00:00:11.229 -- 00:00:16.498 At this time, all participants are in a listen-only mode, and as a reminder, this conference 00:00:16.498 -- 00:00:19.042 call is being recorded. 00:00:19.042 -- 00:00:24.030 This afternoon, NIGEN Biosciences issued a news release announcing the company's financial 00:00:24.030 -- 00:00:27.115 results for the third quarter of 2025. 00:00:27.115 -- 00:00:31.121 If you have not reviewed this information, both are available within the Investor Relations 00:00:31.121 -- 00:00:37.026 section of Niogen Biosciences website at www.niogenscience.com. 00:00:39.192 -- 00:00:44.300 I will now turn the conference over to Kendall Knish, Senior Director of Publicity and 00:00:44.300 -- 00:00:48.483 Public Relations. Please go ahead, Ms. Knish. 00:00:52.211 -- 00:00:56.562 Thank you. Good afternoon, and welcome to Niogen Bioscience, Inc. 00:00:56.562 -- 00:01:01.948 third quarter of 2025 conference call. With us today are Niagen 00:01:01.948 -- 00:01:07.154 Biosciences Chief Executive Officer Rob Fried, Chief Financial Officer 00:01:07.154 -- 00:01:12.600 Ozan Pamir, and Senior Vice President of Scientific and Regulatory Affairs, 00:01:12.600 -- 00:01:18.084 Dr. Andrew Hsiao. Dr. Hsiao will join the call for Q&A. 00:01:18.506 -- 00:01:23.668 Today's conference call may include forward-looking statements including statements related 00:01:23.668 -- 00:01:28.633 to the company's research and development and clinical trial plans and the timing and 00:01:28.633 --...